Advances in neurometabolic therapy
Actovegin is a calf blood extract that contains more than 200 biologically active compounds. Experiments have shown that Actovegin reduces the neurotoxic effect of amyloid, neutralizes reactive oxygen species, and normalizes the endothelial function of small vessels. The drug has not been shown to s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2019-11-01
|
| Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1187 |
| id |
doaj-38b320c4d69545f5837946a47671ff21 |
|---|---|
| record_format |
Article |
| spelling |
doaj-38b320c4d69545f5837946a47671ff212021-07-29T08:58:40ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422019-11-0111312913610.14412/2074-2711-2019-3-129-136904Advances in neurometabolic therapyV. V. Zakharov0N. V. Vakhnina1I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaActovegin is a calf blood extract that contains more than 200 biologically active compounds. Experiments have shown that Actovegin reduces the neurotoxic effect of amyloid, neutralizes reactive oxygen species, and normalizes the endothelial function of small vessels. The drug has not been shown to stimulate tumor growth in the neuroblastoma model. Clinical experience with Actovegin suggests that the drug has an undoubted efficacy in treating moderate vascular cognitive impairment and chronic distal symmetric diabetic polyneuropathy and that it is used as additional therapy for primary degenerative and vascular dementia. The clinical efficacy of Actovegin in chronic obliterating diseases of the lowerlimb arteries is being actively studied now.https://nnp.ima-press.net/nnp/article/view/1187actoveginvascular cognitive impairmentpolyneuropathy |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
V. V. Zakharov N. V. Vakhnina |
| spellingShingle |
V. V. Zakharov N. V. Vakhnina Advances in neurometabolic therapy Nevrologiâ, Nejropsihiatriâ, Psihosomatika actovegin vascular cognitive impairment polyneuropathy |
| author_facet |
V. V. Zakharov N. V. Vakhnina |
| author_sort |
V. V. Zakharov |
| title |
Advances in neurometabolic therapy |
| title_short |
Advances in neurometabolic therapy |
| title_full |
Advances in neurometabolic therapy |
| title_fullStr |
Advances in neurometabolic therapy |
| title_full_unstemmed |
Advances in neurometabolic therapy |
| title_sort |
advances in neurometabolic therapy |
| publisher |
IMA-PRESS LLC |
| series |
Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| issn |
2074-2711 2310-1342 |
| publishDate |
2019-11-01 |
| description |
Actovegin is a calf blood extract that contains more than 200 biologically active compounds. Experiments have shown that Actovegin reduces the neurotoxic effect of amyloid, neutralizes reactive oxygen species, and normalizes the endothelial function of small vessels. The drug has not been shown to stimulate tumor growth in the neuroblastoma model. Clinical experience with Actovegin suggests that the drug has an undoubted efficacy in treating moderate vascular cognitive impairment and chronic distal symmetric diabetic polyneuropathy and that it is used as additional therapy for primary degenerative and vascular dementia. The clinical efficacy of Actovegin in chronic obliterating diseases of the lowerlimb arteries is being actively studied now. |
| topic |
actovegin vascular cognitive impairment polyneuropathy |
| url |
https://nnp.ima-press.net/nnp/article/view/1187 |
| work_keys_str_mv |
AT vvzakharov advancesinneurometabolictherapy AT nvvakhnina advancesinneurometabolictherapy |
| _version_ |
1721250581921660928 |